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a set of independent risk factors. The key findings, relative risks and 95% confidence
intervals were calculated and are presented below.
Results:
Conclusion. The data demonstrate that in renal transplant patients traditional risk factors
such as age, diabetes, previous coronary heart disease and lipid values are major deter-
minants of cardiac risk. The analysis also demonstrates that renal function and rejection
episodes are independent risk factors for cardiac events.
1124-192 Rosiglitazone Reduces Novel Biomarkers of 
Cardiovascular Disease in Subjects With Type 2 
Diabetes Mellitus Already on Statin Therapy
John D. Brunzell, Santica Marcovina, Dahong Yu, Alexander Cobitz, Errol Gould, Hongzi 
Chen, Lisa Porter, University of Washington, Seattle, WA, GlaxoSmithKline, King of 
Prussia, PA
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in type 2 dia-
betes (T2DM). Increased preponderance of small dense LDL particles and decreased
HDL are atherogenic factors associated with insulin resistance (IR) and the metabolic
syndrome. IR is also associated with hypercoagulable and proinflammatory states which
increase CVD risk. In T2DM, treatment with rosiglitazone (RSG) has demonstrated con-
version of the small dense LDL Type B phenotype (LDL Rf < 0.263) to the less athero-
genic Type A phenotype (LDL Rf > 0.263) as well as improvement in concentrations of
additional CVD biomarkers including CRP, PAI-1 and MMP-9. The effect of RSG on CVD
risks factors in T2DM subjects on statin therapy with predominately small dense LDL was
evaluated. Seventy two subjects on diet/exercise, or metformin monotherapy, who had
received at least 8 weeks of statin therapy, and had LDL Rf < 0.263 were randomized to
the addition of placebo (N=14) or RSG 4mg (N=29) or 8mg (N=29) TDD. Results: By
study end (Week 12), 24% (4mg) and 36% (8mg) of patients on RSG had converted to a
pattern of predominately large, buoyant LDL Rf (LDL Rf > 0.263) compared to no conver-
sion in the placebo group. Significant reductions in CRP and PAI-1 were observed in
RSG treated subjects. 
Conclusion: In T2DM subjects on statins, RSG significantly increased LDL particle size 
and reduced CRP and PAI-1, suggesting RSG may reduce CVD events.
1124-193 Dose of Fish Oil Needed to Achieve Cardioprotective 
Blood Levels of Omega-3 Fatty Acids
William S. Harris, Mid America Heart Institute, Kansas City, MO, University of Missouri-
Kansas City, Kansas City, MO
Background: The evidence for a cardioprotective effect of omega-3 fatty acids (FA) has
accumulated to the point where the American Heart Association (AHA) now recommends
that patients with known coronary heart disease (CHD) consume about 1 g/d of eicosap-
entaenoic and docosahexaenoic acids (EPA+DHA), and adults without disease should
eat at least two (preferably oily) fish meals per week. (The latter would provide about 500
mg/d EPA+DHA). Both epidemiological and interventional studies suggest that these
intakes will lower risk for death from CHD by 30%-50%. A variety of studies point to a red
blood cell (RBC) EPA+DHA level (hereafter, called the Omega-3 Index) of >=8% (percent
of total RBC FA) as a reasonable target value for cardioprotection. An Index of <=4% is
associated with relatively high risk. This study was undertaken to determine the effects of
AHA-recommended intakes of omega-3 FA from supplements on the Omega-3 Index.
Methods: Healthy subjects on stable background diets were randomized to supplementa-
tion with either 0 (placebo; n=22), 0.5 g (n=24), or 1.0 g (n=10) of EPA+DHA (ROPUFA-
30, Roche Vitamins). After five months, their Omega-3 Indexes were determined. Com-
pliance was determined by capsule count.
Results: Overall compliance was 95%, and it was not less than 75% for any subject. The
mean (SD) Omega-3 Indexes achieved were 4.3 (1.2%), 8.0 (1.7%), and 10.0 (2.8%),
respectively. Omega-3 Indexes of >=8% were achieved by 5%, 54%, and 80% of those
taking 0, 0.5g and 1.0 g/d, respectively. Indexes of <=4% were observed in 55%, 4% and
10% in each respective group.
Conclusions: These results suggest that most people taking 1 g EPA+DHA/d will achieve
or surpass the 8% target value for the Omega-3 Index, and that about half of those taking
500 mg/d will reach the 8% level. Thus, based upon blood levels likely achieved, AHA
recommended intakes should produce significant cardioprotection. The Omega-3 Index
identifies a risk factor that is easily, safely and inexpensively corrected and may represent
a novel, physiologically-relevant, independent and graded marker of risk for death from
CHD. (Sponsored in part by Roche Vitamins, Inc.).
1124-194 Metabolic Syndrome and Prevention of Premature 
Coronary Artery Disease
Ana Mari Schaper, Kwame Osei Akosah, Vicki Lynn McHugh, Sharon Ione Barnhart, 
Patricia A. Perlock, Troy Haider, Michelle Ann Mathiason, Gundersen Lutheran Health 
System, La Crosse, WI
Background: Metabolic Syndrome (MS) and primary prevention of coronary artery dis-
ease (CAD) is becoming increasingly appreciated. The National Cholesterol Education
Program (NCEP III) guidelines have defined MS and recommended aggressive manage-
ment. Consequently, an emphasis needs to be placed on the identification of persons
with MS. Lipoprotein subclass analysis allows for determination of atherogenic lipopro-
tein traits (ALT) of MS, but its incremental value remains unknown.
Objective: To determine the rate of MS in subjects screened for primary prevention and
to assess incremental value of ALT.
Methods: 254 young adults (women < age 65; men < 55) without known CAD, scheduled
for elective coronary angiogram had labs drawn for lipid and lipoprotein analysis (Lipo-
Science, Inc). MS per NCEP III was defined as the presence of >3 of the following traits:
low HDL (men <40 mg/dL; women <50 mg/dL), high triglyceride (> 150 mg/dL), hyperten-
sion (>130/85 mm Hg), fasting glucose (> 110 mg/dL), and BMI >30. ALT was defined as
>2 of the following values determined by nuclear magnetic resonance spectroscopy
(NMR): small LDL pattern B (< 20.5 nm), reduced large HDL (<11 mg/dL) and elevated
large VLDL (>27 mg/dL). CAD was defined as stenosis severity of > 50%
Results: Mean age was 53±8. 82% were overweight or obese. The mean total, LDL, and
HDL cholesterol levels were acceptable per NCEP III and not statistically different
between subjects with and without CAD. Mean triglyceride (170 versus 138 mg/dL,
p=0.002) and glucose (139 versus 109 mg/dL, p=0.005) were higher in those with CAD.
MS was present in 59 (24%) of participants. ALT was present in 85 (35%) of participants.
73 participants met criteria for CAD, of whom 26 (36%) had MS, and 35 (48%) had ALT.
The odds for MS in predicting CAD were 2.3 (CI: 1.3-4.2, p=0.006). The odds for ALT
were 2.2 (CI: 1.2-3.9, p=0.007). Using either criterion, as many as 43 (59%) of subjects
with CAD were identified (OR=2.6, CI: 1.5-4.5, p<0.001).
Conclusion: In a population of young adults with high levels of obesity and elevated trig-
lyceride, the use of both of these definitions provides incremental value in identifying
high-risk young adults who should be targeted for aggressive risk modification.
1124-195 Anthropomorphic Predictors of Insulin Sensitivity in a 
Healthy Population
Justo Sierra Johnson, Bruce D. Johnson, Kent R. Bailey, Stephen T. Turner, Mayo Clinic, 
Rochester, MN
Background: Insulin sensitivity (SI) is the capability of insulin to increase glucose dis-
posal. Abdominal fat distribution has been associated with insulin sensitivity. However, it
is not clear whether sophisticated measures (DEXA scanning) of body fat and fat distribu-
tion are better predictors of SI than simple measures (BMI, waist and hip circumferance,
waist-to-hip ratioWHR). Methods: We studied 256 healthy Caucasian subjects from
Rochester, MN (age 19-60, 133 women) who were admitted to the GCRC for measure-
ment of SI using the minimal model technique. All subjects had the simple and the
sophisticated measures of body fat distribution taken. Body fat measures were analyzed
and compared individually (controlling for age and gender) and in multiple regression
models, in relation to SI. Results: Among simple measures: waist circumferance and BMI
had the best correlations with SI (see Table), while the corresponding best predictors
among the DEXA measures were: head fat (raw and percent) and upper body fat. When
WHR and BMI were combined, or when head fat and upper body fat were combined, the
Risk factors at baseline (RR for) Univariate RR Multivariate RR
Age, years, 1 extra year 1.04 (1.02,1.05) 1.03 (1.01, 1.06)
Diabetes, Yes/No 2.35 (1.56, 2.35) 2.13 (1.32, 3.46)
Treatment for rejections, Yes/No 1.47 (1.00, 2.16) 1.5(1.01, 2.48)
Coronary heart disease, Yes/No 3.28 (2.08, 5.18) 2.11 (1.23, 3.62)
Total cholesterol, (1 extra mmol/L ) 1.31 (1.12, 1.55) 1.21 (0.97, 1.50)
LDL cholesterol (1 extra mmol/L ) 1.41 (1.18, 1.69) 1.34 (1.09, 1.66)
HDL Cholesterol (1extra mmol/L ) 0.55 (0.34, 0.90) 0.56 (0.31, 1.02)
Triglycerides (1extra mmol/L ) 1.11 (1.03, 1.19)
ST-T abnromalities, Yes/No 2.02 (1.32, 3.08)
Pulse Pressure (1 extra mmHg) 1.01 (1.00, 1.02)
Serum creatinine (10 extra umol/L) 1.05 (1.02, 1.08 1.05 (1.01, 1.09)
Aspirine use, Yes/No 1.65 (1.08, 2.54)
Placebo
N=14
RSG 4 mg
N=29
RSG 8 mg
N=29
% patients converted to
LDL Rf > 0.263 (%)
0 23.5 36*
Mean ∆ & %∆ (95% ci) from 
baseline:
LDL Rf -0.0003
(-0.0112, 0.0107)
0.011*
(0.0033, 0.0187)
0.014*
(0.0069, 0.0212)
CRP (%) 17.26
(-18.41, 68.50)
-35.38*
(-49.67, -17.05)
-39.08*
(-52.36, -22.10)
PAI-1 antigen (%) -22.69
(-42.12, 3.28)
-10.63
(-26.81, 9.13)
-22.65*
(-37.05, -4.96)
PAI-1 activity (%) -29.02
(-57.08, 17.38)
-17.30
(-41.45, 16.83)
-30.72*
(-51.14, -1.76)
MMP-9 (%) 20.13
(-14.59, 68.97)
-8.70
(-27.39, 14.79)
-17.76
(-34.44, 3.17)
* Statisticallysignificant
